



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/884,696	06/19/2001	Lisle W. George	481.06	4037	
22798 75	90 11/15/2005		EXAM	EXAMINER	
QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.			PORTNER, VIRGINIA ALLEN		
POBOX 458 ALAMEDA, CA 94501			ART UNIT	PAPER NUMBER	
			1645		
			DATE MAILED: 11/15/2005		

Please find below and/or attached an Office communication concerning this application or proceeding.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)
09/884,696	GEORGE ET AL.
Examiner	Art Unit
Ginny Portner	1645

zororo uro rumig or an ruppour ziror	Examiner	Art Onit					
•	Ginny Portner	1645					
The MAILING DATE of this communication appe	ars on the cover sheet with the c	orrespondence add	ress				
THE REPLY FILED 06 October 2005 FAILS TO PLACE THIS A	APPLICATION IN CONDITION FOR	R ALLOWANCE.					
 The reply was filed after a final rejection, but prior to or or this application, applicant must timely file one of the follow places the application in condition for allowance; (2) a No a Request for Continued Examination (RCE) in compliance 	wing replies: (1) an amendment, aff otice of Appeal (with appeal fee) in c	idavit, or other evider compliance with 37 C	nce, which FR 41.31; or (3)				
time periods: a) The period for reply expiresmonths from the mailing.	g date of the final rejection.						
b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection.							
Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).							
Extensions of time may be obtained under 37 CFR 1.136(a). The date	on which the petition under 37 CFR 1.1	36(a) and the appropria	te extension fee				
have been filed is the date for purposes of determining the period of exunder 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office late may reduce any earned patent term adjustment. See 37 CFR 1.704(b)	tension and the corresponding amount shortened statutory period for reply orig r than three months after the mailing da	of the fee. The appropr inally set in the final Offi	iate extension fee ce action; or (2) as				
NOTICE OF APPEAL 2. The Notice of Appeal was filed on A brief in compliance with 37 CFR 41.37 must be filed within two months of the date of							
filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since							
a Notice of Appeal has been filed, any reply must be filed							
AMENDMENTS	•						
The proposed amendment(s) filed after a final rejection,	but prior to the date of filing a brief,	will not be entered b	ecause				
(a) They raise new issues that would require further consideration and/or search (see NOTE below);							
 (b) ☐ They raise the issue of new matter (see NOTE below) (c) ☐ They are not deemed to place the application in be 	•	ducina or simplifyina	the issues for				
appeal; and/or	tter form for appear by materially re	ducing or simplifying	110 133003 101				
(d) They present additional claims without canceling a	corresponding number of finally rej	ected claims.					
NOTE: See Continuation Sheet. (See 37 CFR 1.1	16 and 41.33(a)).						
4. \square The amendments are not in compliance with 37 CFR 1.1		mpliant Amendment	(PTOL-324).				
Applicant's reply has overcome the following rejection(s)							
 Newly proposed or amended claim(s) <u>13 and 14</u> would the non-allowable claim(s). 	·	•	•				
7. For purposes of appeal, the proposed amendment(s): a) will not be entered, or b) will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended. The status of the claim(s) is (or will be) as follows:							
Claim(s) allowed:			,				
Claim(s) objected to: <u>13 and 14</u> .							
Claim(s) rejected: <u>13,14,49,50,55 and 56</u> .							
Claim(s) withdrawn from consideration: <u>1-4,6,12,34-48 and 51-54.</u> <u>AFFIDAVIT OR OTHER EVIDENCE</u>							
B. ☐ The affidavit or other evidence filed after a final action, but	it before or on the date of filing a Ni	ntice of Appeal will no	nt he entered				
because applicant failed to provide a showing of good an was not earlier presented. See 37 CFR 1.116(e).	d sufficient reasons why the affiday	rit or other evidence is	s necessary and				
 The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to 	overcome <u>all</u> rejections under appea	al and/or appellant fai	Is to provide a				
showing a good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(d)(1). The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached.							
TO. ☐ The amidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER	on of the status of the claims after e	ntry is below or attact	ned.				
 The request for reconsideration has been considered by <u>See Continuation Sheet.</u> 	at does NOT place the application in	n condition for allowa	nce because:				
12. Note the attached Information Disclosure Statement(s).	(PTO/SB/08 or PTO-1449) Paper N	lo(s).					
13. Other:	, , , , , , , , , , , , , , , , , , ,	ANTA MININA	Jackeld 1807 11NER 105				
•		PRIMARY/EXAM	MINER				
		11/08	<i>(</i> り				

Application No. 09/884,696

Continuation Sheet (PTO-303)

j u

the

Continuation of 3. NOTE: Amended Claim 55 is proposed to recite new claim limitations, specifically "comprises a subsequence heterologus to the M.bovis cytotoxin polypeptide of SEQ ID NO 2", which sets forth a combination of claim limitations not considered prior to the Final Office action. New claims 57-59 have not been previously considered on the record prior to the Final Office Action and therefore raise new issues After Final

Continuation of 11. does NOT place the application in condition for allowance because: the amendment After Final was not entered because the claim amendment of claim 55, and newly submitted claims 57-59 raise new issues After Final. Traversal is directed to a combination of claim limitations not entered..